


BRIDGEBIO

Diagnosing
and Managing

ATTR Cardiomyopathy




BridgeBio is a trademark of BridgeBio Pharma, Inc.
All other trademarks are property of their respective owners.
© 2026 BridgeBio Pharma, Inc. All rights reserved.

MAT-US--190 V3

ATTR-Cardiac Amyloidosis Diagnosis and Management

Adapted from Kittleston MM, et al. *J Am Coll Cardiol*. 2025.



Evidence is insufficient to recommend combination stabilizer and silencer therapy or change of therapy if disease progresses.

ACEI=angiotensin-converting enzyme inhibitor; AL-CM=light chain amyloid cardiomyopathy; ARB=angiotensin receptor blocker; ARNI=angiotensin receptor-neprilysin inhibitor; ATTR-CM=transthyretin cardiac amyloidosis; ATTRv=variant transthyretin-mediated amyloidosis; ATTRwt=wild-type transthyretin-mediated amyloidosis; CT=computed tomography; EKG=electrocardiogram; eGFR=estimated glomerular filtration rate; HF=heart failure; K/L=kappa/lambda; MGUS=monoclonal gammopathy of undetermined significance; MRA=mineralocorticoid antagonist; SGLT2=sodium-glucose cotransporter-2; SPECT=single-photon emission computed tomography.

Adapted from Kittleston MM, et al. *Transthyretin cardiac amyloidosis evaluation and management: 2025 ACC concise clinical guidance: a report of the American College of Cardiology Solution Set Oversight Committee*. *J Am Coll Cardiol*. 2023. Page 1085. With permission from Elsevier.

Laboratory Parameters to Aid in ATTR-CM Diagnosis or Management¹⁻⁶

Low serum TTR (prealbumin)*

Elevated or rising
NT-proBNP

Elevated or rising troponin
(high sensitivity)

Low or decreasing eGFR[†]

Criteria for Evaluating ATTR-CM Progression⁷

Evaluate changes annually relative to 12 months prior

- ✓ HF-related hospitalization
- ✓ Oral diuretic intensification
- ✓ Increase in NT-proBNP
- ✓ Decrease in eGFR
- ✓ Decrease in 6MWD
- ✓ QoL (decrease in KCCQ-OS or increase in NYHA functional class)

Progression can be considered if ≥2 parameters meet their defined threshold



Scan the QR code to learn about the warning signs of ATTR-cardiac amyloidosis



*Serum TTR (baseline and early changes upon treatment initiation) may be an independent prognostic factor.^{5,6}

[†]An eGFR decrease from ≥45 mL/min to <45 mL/min indicates advancement in NAC staging score and disease progression.⁶

6MWD=6-minute walk distance; ATTR-CM=transthyretin amyloid cardiomyopathy; eGFR=estimated glomerular filtration rate; HF=heart failure; KCCQ-OS=Kansas City Cardiomyopathy Questionnaire Overall Summary; NAC=National Amyloidosis Centre; NT-proBNP=N-terminal pro-B-type natriuretic peptide; NYHA=New York Heart Association; QoL=quality of life; TTR=transthyretin.

References:

1. Garcia-Pavia P, et al. *Eur J Heart Fail.* 2021;23(6):895-905.
2. Hanson JLS, et al. *Circ Heart Fail.* 2018;11(2):e004000.
3. Kittleson MM, et al. *J Am Coll Cardiol.* 2025;S0735-1097(25)07719-8.
4. Gillmore JD, et al. *Eur Heart J.* 2018;39(30):2799-2806.
5. Minervini A, et al. *Eur J Intern Med.* 2025;106350.
6. Maurer MS, et al. *J Am Coll Cardiol.* 2025 May 27;85(20):1911-1923.
7. Garcia-Pavia P, et al. *JACC Heart Fail.* 2025;26:102766.